復宏漢霖(02696.HK)披露治療肺癌藥物「斯魯利單抗」III期臨牀研究數據
復宏漢霖(02696.HK)公佈,在既往未接受過治療的廣泛期小細胞肺癌(ES-SCLC)患者中開展的比較斯魯利單抗(創新抗PD-1單抗)聯合化療,及安慰劑聯合化療的有效性和安全性的隨機、雙盲、國際多中心、III期臨牀研究(ASTRUM-005)期中分析詳細數據。
研究結果顯示,斯魯利單抗聯合卡鉑-依託泊(甘)在總體人羣和中國亞組均可延長中位總生存期(OS),斯魯利單抗組和安慰劑組的總人羣中位OS分別爲15.38個月和11.1個月,總人羣降低死亡風險達38%(中國亞組達41%),p <0.001,兩個給藥組的2年總生存率(OSR)分別爲43.2%和8%,且具有良好的安全性。這一結果標誌着斯魯利單抗有望成爲全球首個一線治療SCLC的抗PD-1單抗,爲小細胞肺癌患者提供全新的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.